Targeting the Insulin-like Growth Factor Axis for the Development of Novel Therapeutics in Oncology
Authors:
- 1 January 2012
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 72 (1) , 3-12
Abstract
Insulin-like growth factors (IGF) are polypeptide hormones with potent anabolic and mitogenic effects that regulate cell growth and differentiation. Dysregulation of the IGF axis has been well documented in the development and progression of multiple types of cancer. As a result, compounds targeting the IGF axis have become an area of intense preclinical and clinical research for cancer therapeutics. The IGF axis is intimately involved with the insulin-signaling pathway because of their close homologies. This homology may explain hurdles encountered in the clinical development of IGF-targeted therapies, such as less-than-expected antitumor efficacy that may arise from compensatory increases in the activity of insulin receptor isoform A (IR-A), in response to IGF-I receptor (IGF-IR) inhibition and perturbations in glucose homeostasis, arising from the inhibition of insulin receptor isoform B (IR-B) activity. In this brief review, we compare differentiating factors that characterize the 3 major classes of IGF-targeting compounds: therapeutic antibodies that target IGF-IR, small molecule tyrosine kinase inhibitors that inhibit kinase activities of IGF-IR and IR, and antibodies that target IGF ligands. Cancer Res; 72(1); 3–12. ©2012 AACR.Keywords
This publication has 40 references indexed in Scilit:
- Targeting the Insulin-Like Growth Factor 1 Receptor in Ewing's Sarcoma: Reality and ExpectationsSarcoma, 2011
- Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumabBritish Journal of Cancer, 2010
- Small Is Beautiful: Insulin-Like Growth Factors and Their Role in Growth, Development, and CancerJournal of Clinical Oncology, 2010
- The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label studyBritish Journal of Cancer, 2010
- Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort studyThe Lancet Oncology, 2010
- The Insulin-like Growth Factor-1 Receptor–Targeting Antibody, CP-751,871, Suppresses Tumor-Derived VEGF and Synergizes with Rapamycin in Models of Childhood SarcomaCancer Research, 2009
- Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinomaCancer Chemotherapy and Pharmacology, 2009
- The insulin receptor substrate-1: A biomarker for cancer?Experimental Cell Research, 2009
- IGF-1 Receptor Inhibitors in Clinical Trials—Early LessonsJournal of Mammary Gland Biology and Neoplasia, 2008
- Insulin-Like Growth Factor-I Activates Gene Transcription Programs Strongly Associated With Poor Breast Cancer PrognosisJournal of Clinical Oncology, 2008